Data as of Sep 30
| -0.048 / -0.36%|
The 2 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 26.00, with a high estimate of 27.00 and a low estimate of 25.00. The median estimate represents a +97.42% increase from the last price of 13.17.
The current consensus among 2 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.